{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:27:34Z","timestamp":1786660054535,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01068-2","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T04:51:17Z","timestamp":1766724677000},"page":"595-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk\/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study"],"prefix":"10.1038","volume":"29","author":[{"given":"Tangtao","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-2526","authenticated-orcid":false,"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-7205","authenticated-orcid":false,"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1023-9824","authenticated-orcid":false,"given":"Junlong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, et al. NCCN Guidelines Insights: prostate cancer early detection, Version 1.2023. J Natl Compr Canc Netw. 2023;21:236\u201346. https:\/\/doi.org\/10.6004\/jnccn.2023.0014.","journal-title":"J Natl Compr Canc Netw"},{"key":"1068_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cncr.31833","volume":"125","author":"D Sundi","year":"2019","unstructured":"Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer. 2019;125:391\u20137. https:\/\/doi.org\/10.1002\/cncr.31833.","journal-title":"Cancer"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","volume":"53","author":"MF Langelier","year":"2018","unstructured":"Langelier MF, Eisemann T, Riccio AA, Pascal JM. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018;53:187\u201398. https:\/\/doi.org\/10.1016\/j.sbi.2018.11.002.","journal-title":"Curr Opin Struct Biol"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pharmthera.2018.03.006","volume":"188","author":"Y Lu","year":"2018","unstructured":"Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy. Pharm Ther. 2018;188:168\u201375. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.006.","journal-title":"Pharm Ther"},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"key":"1068_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdz192.","journal-title":"Ann Oncol"},{"key":"1068_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374. https:\/\/doi.org\/10.1038\/s41467-017-00393-y.","journal-title":"Nat Commun"},{"key":"1068_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor\u2013induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479. https:\/\/doi.org\/10.1126\/scisignal.aam7479.","journal-title":"Sci Signal"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0120.","journal-title":"Cancer Discov"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-0716-2891-1_19","volume":"2609","author":"P Makhov","year":"2023","unstructured":"Makhov P, Fazliyeva R, Tufano A, Uzzo RG, Kolenko VM. Examining the effect of PARP-1 inhibitors on transcriptional activity of androgen receptor in prostate cancer cells. Methods Mol Biol. 2023;2609:329\u201335. https:\/\/doi.org\/10.1007\/978-1-0716-2891-1_19.","journal-title":"Methods Mol Biol"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","volume":"84","author":"L Kostos","year":"2024","unstructured":"Kostos L, Burbury K, Azad AA. Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer. Drugs. 2024;84:1093\u2013109. https:\/\/doi.org\/10.1007\/s40265-024-02071-y.","journal-title":"Drugs"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","volume":"293","author":"AS Bachmann","year":"2018","unstructured":"Bachmann AS, Geerts D. Polyamine synthesis as a target of MYC oncogenes. J Biol Chem. 2018;293:18757\u201369. https:\/\/doi.org\/10.1074\/jbc.TM118.003336.","journal-title":"J Biol Chem"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","volume":"7","author":"C Messina","year":"2024","unstructured":"Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: A quantitative synthesis and meta-analysis. Eur Urol Oncol. 2024;7:179\u201388. https:\/\/doi.org\/10.1016\/j.euo.2023.07.013.","journal-title":"Eur Urol Oncol"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib for metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:1620\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9.","journal-title":"Lancet Oncol"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0394.","journal-title":"Clin Cancer Res"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23:362\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(21)00757-9.","journal-title":"Lancet Oncol"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2214676.","journal-title":"N Engl J Med"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108. https:\/\/doi.org\/10.1016\/S1470-2045(23)00382-0.","journal-title":"Lancet Oncol"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:3339\u201351. https:\/\/doi.org\/10.1200\/JCO.22.01649.","journal-title":"J Clin Oncol"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00684-1.","journal-title":"Lancet"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245\u201350. https:\/\/doi.org\/10.1016\/j.urology.2010.01.027.","journal-title":"Urology"},{"key":"1068_CR25","doi-asserted-by":"publisher","first-page":"132590","DOI":"10.1016\/j.jhazmat.2023.132590","volume":"461","author":"M Liu","year":"2024","unstructured":"Liu M, Hong Y, Duan X, Zhou Q, Chen J, Liu S, et al. Unveiling the metal mutation nexus: Exploring the genomic impacts of heavy metal exposure in lung adenocarcinoma and colorectal cancer. J Hazard Mater. 2024;461:132590. https:\/\/doi.org\/10.1016\/j.jhazmat.2023.132590.","journal-title":"J Hazard Mater"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"e24977","DOI":"10.1002\/jcla.24977","volume":"37","author":"H Chen","year":"2023","unstructured":"Chen H, Wang B, Zhang Y, Shu Y, Dong H, Zhao Q, et al. A unified DNA- and RNA-based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors. J Clin Lab Anal. 2023;37:e24977 https:\/\/doi.org\/10.1002\/jcla.24977.","journal-title":"J Clin Lab Anal"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw"},{"key":"1068_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"key":"1068_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","volume":"80","author":"JE Berchuck","year":"2021","unstructured":"Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GM, et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer. Eur Urol. 2021;80:295\u2013303. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.031.","journal-title":"Eur Urol"},{"key":"1068_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","volume":"76","author":"E Efstathiou","year":"2019","unstructured":"Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol. 2019;76:418\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.010.","journal-title":"Eur Urol"},{"key":"1068_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","volume":"18","author":"G Devos","year":"2021","unstructured":"Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18:739\u201362. https:\/\/doi.org\/10.1038\/s41585-021-00514-9.","journal-title":"Nat Rev Urol"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.21873\/anticanres.11672","volume":"37","author":"JC Hu","year":"2017","unstructured":"Hu JC, Hung SC, Ou YC. Assessments of neoadjuvant hormone therapy followed by robotic-assisted radical prostatectomy for intermediate- and high-risk prostate cancer. Anticancer Res. 2017;37:3143\u201350. https:\/\/doi.org\/10.21873\/anticanres.11672.","journal-title":"Anticancer Res"},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","volume":"205","author":"RR McKay","year":"2021","unstructured":"McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, et al. Outcomes of post-neoadjuvant intense hormone therapy and surgery for high-risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol. 2021;205:1689\u201397. https:\/\/doi.org\/10.1097\/JU.0000000000001632.","journal-title":"J Urol"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.eururo.2025.01.015","volume":"87","author":"P Ravi","year":"2025","unstructured":"Ravi P, Kwak L, Acosta AM, Rastogi S, Xie W, Abdelnaser A, et al. Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer. Eur Urol. 2025;87:643\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2025.01.015.","journal-title":"Eur Urol"},{"key":"1068_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","volume":"68","author":"L Bourke","year":"2015","unstructured":"Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol. 2015;68:374\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.023.","journal-title":"Eur Urol"},{"key":"1068_CR36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250\u201361. https:\/\/doi.org\/10.1056\/NEJMoa074311.","journal-title":"N Engl J Med"},{"key":"1068_CR37","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s11136-015-0993-8","volume":"24","author":"CK Wong","year":"2015","unstructured":"Wong CK, Choi EP, Tsu JH, Ho BS, Ng AT, Chin WY, et al. Psychometric properties of Functional Assessment of Cancer Therapy\u2013Prostate (FACT-P) in Chinese patients with prostate cancer. Qual Life Res. 2015;24:2397\u2013402. https:\/\/doi.org\/10.1007\/s11136-015-0993-8.","journal-title":"Qual Life Res"},{"key":"1068_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2217\/cer.14.41","volume":"3","author":"D Chu","year":"2014","unstructured":"Chu D, Popovic M, Chow E, Cella D, Beaumont JL, Lam H, et al. Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. J Comp Eff Res. 2014;3:523\u201331. https:\/\/doi.org\/10.2217\/cer.14.41.","journal-title":"J Comp Eff Res"},{"key":"1068_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/pon.5372","volume":"29","author":"T Guan","year":"2020","unstructured":"Guan T, Santacroce SJ, Chen DG, Song L. Illness uncertainty, coping, and quality of life among patients with prostate cancer. Psychooncology. 2020;29:1019\u201325. https:\/\/doi.org\/10.1002\/pon.5372.","journal-title":"Psychooncology"},{"key":"1068_CR40","doi-asserted-by":"publisher","first-page":"CD006019","DOI":"10.1002\/14651858.CD006019.pub2","volume":"2006","author":"S Kumar","year":"2006","unstructured":"Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006:CD006019. https:\/\/doi.org\/10.1002\/14651858.CD006019.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1068_CR41","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","volume":"72","author":"M Lardas","year":"2017","unstructured":"Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review. Eur Urol. 2017;72:869\u201385. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.035.","journal-title":"Eur Urol"},{"key":"1068_CR42","doi-asserted-by":"publisher","first-page":"13145","DOI":"10.1002\/cam4.5997","volume":"12","author":"F Ciardiello","year":"2023","unstructured":"Ciardiello F, Bang YJ, Cervantes A, Dvorkin M, Lopez CD, Metges JP, et al. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Cancer Med. 2023;12:13145\u201354. https:\/\/doi.org\/10.1002\/cam4.5997.","journal-title":"Cancer Med"},{"key":"1068_CR43","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","volume":"28","author":"X Wu","year":"2022","unstructured":"Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, et al. Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study. Clin Cancer Res. 2022;28:653\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1186.","journal-title":"Clin Cancer Res"},{"key":"1068_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","volume":"39","author":"R Krishnakumar","year":"2010","unstructured":"Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2010.06.017.","journal-title":"Mol Cell"},{"key":"1068_CR45","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.xcrm.2025.102018","volume":"6","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wang B, Wei Y, Gan H, Fang B, Li X, et al. Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): a single-arm phase 2 study. Cell Rep Med. 2025;6:102018. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102018.","journal-title":"Cell Rep Med"},{"key":"1068_CR46","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","volume":"87","author":"SAA Naqvi","year":"2025","unstructured":"Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, et al. Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis. Eur Urol. 2025;87:626\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2024.12.007.","journal-title":"Eur Urol"},{"key":"1068_CR47","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41391-024-00887-z","volume":"28","author":"AV Serritella","year":"2025","unstructured":"Serritella AV, Taylor A, Haffner MC, Abida W, Bryce A, Karsh LI, et al. Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). Prostate Cancer Prostatic Dis. 2025;28:601\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00887-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1068_CR48","doi-asserted-by":"publisher","unstructured":"PREVALENCE Study Group. A prospective study to determine the prevalence of DNA repair defects in patients with advanced prostate cancer (PREVALENCE). Ann Oncol. 2023;34:S993. Abstract 1835P. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2783.","DOI":"10.1016\/j.annonc.2023.09.2783"},{"key":"1068_CR49","doi-asserted-by":"publisher","unstructured":"Genetic landscape of advanced prostate cancer. Oncol Times. 2023;45:11. https:\/\/doi.org\/10.1097\/01.COT.0000997464.60422.00.","DOI":"10.1097\/01.COT.0000997464.60422.00"},{"key":"1068_CR50","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.critrevonc.2024.104609","volume":"207","author":"CC Tzang","year":"2025","unstructured":"Tzang CC, Wu HW, Luo CA, Li YT, Kang YF, Hsieh CM, et al. Efficacy and safety of PARP inhibitors in prostate cancer: an umbrella review of systematic reviews and meta-analyses. Crit Rev Oncol Hematol. 2025;207:104609. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104609.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01068-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:44:56Z","timestamp":1786657496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01068-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}